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Sarcoidosis is a granulomatous disease with
worldwide prevalence estimated as high as
300 per million1, 2. Sarcoidosis affects all or-
gans of  the body, but the lungs and intra-
-thoracic lymph nodes are affected in approx-
imately 90% of patients accounting for the
major morbidity and mortality3, 4.
The clinical progression of  sarcoidosis is well
documented5. Indeed, it is known that patients
who present with hilar-adenopathy on chest
roentgenogram as the sole abnormality and
those with erythema nodosum do well two
years later6,7. In contrast sarcoidosis patients
with lupus pernio only had an 20% chance of
resolution at two years7. Although there is
evidence of  genetic predisposition8, no test
helps the clinician predict the outcome of  sar-
coidosis patients on presentation or at times
of  relapse. Therefore, identification of  sar-
coidosis biomarkers remains an unmet need.
The molecular pathogenesis of  sarcoidosis
remains unsettled, however it is clear that ac-
tivated T cells and macrophages (mf) are key
players9,10,11,12. These cells accumulate in the
tissues forming granulomas and can also be
identified in the bronchoalveolar lavage (BAL).
Because proteins govern cell physiology, a
comprehensive analysis of  sarcoidosis BAL
cell-associated proteins may identify much
needed biomakers. A comprehensive analysis
of  the protein equivalent of  a gnome is known
as “the proteome”. Therefore, we studied the
sarcoidosis CD14+ derived proteome.
Proteomics workflow includes: protein separa-
tion and assessment of  fold differences followed
by identification of  selected proteins via mass
spectrometry (MS). Protein separation can be
accomplished by two dimensional gel electro-
phoresis (2DE13) or multidimensional, high per-
formance liquid chromatography (HPLC) pro-
tein identification technology (MUDPIT14,15).
Under MUDPIT, peptides are produced from
the entire extract followed by several in-line,
modes of  HPLC [cation exchanges (SCX), and
reverse phase (RP)]. The last step is always an
RP, so that peptides elute in organic solvent
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which is easily vaporized at the front end of  mass
spectrometer. Mudpit can identify several thou-
sand proteins but does not allow up-front selec-
tion of differentially expressed proteins; hence
called “shotgun proteomics”.
On the contrary 2DE produces a mathematical
matrix for each experimental condition where a
spot can be identified by its x-y coordinates cor-
responding to specific Pi and Mr. values. Spots
are defined as gray pixel areas fitting a Gaussian
model while and non-Gaussian pixels surround-
ing spots are considered “background”. After
background subtraction, spots are quantified
using a transform of  diameter and pixel intensi-
ty. For analysis two gels are overlaid at a time
(termed differential display). To correct for var-
iations in spot position due to (shift during scan-
ning, swelling and shrinking during staining, in-
homogeneities in the gel, temperature or current
variations), matching vectors are created and a
warping algorithm executed16.
To address the sarcoidosis proteome, patients
who required bronchoscopy and BAL as part
of  the workup for an interstitial lung disease
(ILD) were recruited. The protocol was ap-
proved by IRBs, and all patients signed in-
formed consent. BAL was performed as de-
scribed17. A total of 1516 spots comprised
the sarcoidosis proteome, of  these 383 were
up-regulated over two-fold and 294 over 10
fold when compared with the proteome of
the patients without ILD (Fig. 1).
Comparisons between two samples can also be
performed using differential gel electrophoresis
(DIGE)18. Under DIGE experimental and con-
trol samples are each covalently linked to a fluor-
ochrome (Cy3 and Cy5, Amersham), mixed and
resolved in a single gel, so that spots will be lo-
cated at the same x-y coordinates regardless of
gel distortion. However, since only three dyes
exist, the number of  comparisons is limited. On
the other hand, using our approach, a proteome
simply becomes a mathematical matrix, allow-
ing unlimited comparisons.
This feature is very practical for our studies
because the optimal control in sarcoidosis is
not clear. Indeed, in an attempt to control for
“normal” cells, we utilized cells from patients
who presented with hemoptisis but had nor-
mal bronchoscopy since this procedure is not
standard of  care for healthy individuals. Be-
Fig. 1 – Differential display analysis between CDl4+
cellular proteomes of sarcoidosis and a patient without
ILD. Upon completion of bronchoscopy BAL was centrifuged
at 400xg, and the cell pellet incubated with anti-Cd14+ para-
magretic beads (Dynal). Positively selected cells were lyzed
in Trizol (Invitrogen) and the protein pellet resuspended in
IEF buffer (9.5M Urea, 05% CHAPS, 0.4% DTT, 0.5% (v/v)
Pharmalyte 4-7). After ioselectric focusing on 24cm IPG strips
(pH 4-7 L G&E Healthcare), DTT and iodoacetamide
treatments, PAGE was performed using custom-made 25x25
cm gels. After scanning on an infrared instrument (Licor),
quantification and warping using the software Delta 2D
(decodon.com), spots sharing the same x,y coordinates were
compared. Spots upregulated in sarcoidosis (ratio over 2)
were selected, and over 10 fold (shaded). Spots down
regulated in sarcoidosis (ratio below 0.5) were colored in
green but not studied. Yellow spots were present evenly in
both samples (ration 0.48 to 1.98). The control gel in this
analysis comprised CD14+ cells isolated from a patient
without ILD (5*10^6 cell equivalents) and bronchoscoped five
days after an unexplained episode of hemoptisis. Gels have
been repeated at least three times.
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cause of  this, the mφ may have been resting,
thus accounting for the dissimilar proteomes.
Therefore, to narrow the array of  upregulat-
ed sarcoidosis spots, the proteome of  mφ nat-
urally activated in the human lung were puri-
fied from biopsy proven desquamative
insterstitial pneumonia (DIP, Fig. 2).
Surprisingly, the proteomes were diametrically
different. However the DIP mφ becomes stim-
ulated by cigarette smoking and never form gran-
ulomas suggesting that the activation pathways
between the two diseases are different. To con-
trol for activated normal human CD14+ cells,
the procedure described in Fig. 1 was used to
purify CD14+ from the peripheral blood (PBL)
of  healthy volunteers (n=10). However, neither
resting nor PMA/ionomycin stimulated PBL-
-derived mφ-proteomes changed the sarcoido-
sis CD14+-BAL array (data not shown).
However, alveolar mφ and PBL-mφ are obvi-
ously different cells and it is not difficult to dif-
ferentiate sarcoidosis from a non-ILD patient.
A more relevant clinical challenge is to exclude
other ILDs, and cancer. Therefore proteomes
from patients with biopsy proven ILD n=9 were
analyzed. After 2DE, scanning, spot detection,
background subtraction and spot quantification,
a mathematical matrix was prepared for each
condition and all spots integrated into a large
matrix n=23960 spots. This matrix was next used
to identify spots shared between sarcoidosis and
hypersensitivity pneumonitis (HP; both drug
induced and caused by animal droppings) since
these diseases could be clinically and sometimes
pathologically similar. Indeed a large number of
sarcoidosis spots had comparable x.y coordinates
and spot intensities in the HP proteomes (Fig. 3).
Fig. 2 – Differential display analysis between sarcoi-
dosis and DIP CD14+ cellular proteomes. CD14+ cells
(5*10^6 cell equivalents) from a patient with DIP were
purified with paramagnetic beads resolved on 2D-gels and
compared with the sarcoidosis proteome shown in Fig. 1.
Strikingly, 624 spots were upregulated over 5 fold in
sarcoidosis (red spots surrounded by white circles) while
only a few spots were shared. Spots found only in DIP were
identified in green but not studied further.
Fig. 3 – Multi-dimensional differential display analysis of
CDl4+ cellular proteomes and other granulomatosis. CDI4+
cells were purified from BAL of patiens with the following biopsy
proven ILDs: Hypersensitivity pneumonitis (HP) induced by a
drug and by animal droppings, DIP, pumonary alveolar
proteinosis (pAP), pulmonary Langerhans cell histiocytosis
(PLCH), Coccidioidomycosis pneumonia (Cocci as a
representative of other granulomatosis) and patients without
ILD (hemoptisis, described in Fig. 1). Gels were prepared as
described in the preceding figures, mathematical matrixes
computed and integrated into a large matrix containing all spots
n=23960. This matrix was next used to compute fold rations
between 0.48 and 1.98 between sarcoidosis and HP caused
by animal droppings (purple), sarcoidosis and drug-induced
HP (light purple) as well as sarcoidosis and DIP (blue). Black
spots did not fit the search criteria (were not shared between
these diseases). Spots Note that a high fold ratío does not
equate with high abundance.
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These shared spots may relate to molecules
involved in granuloma formation and will be
the focus of  further analysis. To narrow this
array of  “granuloma” spots three patients with
tuberculosis were studied but their cells did
not resolve well on 2DE (data not shown).
Interestingly, DIP and sarcoidosis did not have
many shared molecules (Fig. 3) confirming the
analysis presented in Fig. 2 and reinforcing
the conclusion that the DIP and sarcoidosis
mφ have different activation pathways.
This large mathematical matrix was next used
to identify sarcoidosis spots upregulated over
3 fold over all (Fig. 4). The importance of
this analysis is that, it identified 1516 spots
in the sarcoidosis proteome, of  which 383
were not present in non-ILD proteome but
only 97 persisted after exclusion of  spots
present with ratios as low as 0.3 in 7 ILDs.
Obviously the analysis is not complete be-
cause more proteomes from other granulo-
matous and disease additional ILDs should
be added to fine-tune the sarcoidosis array.
In conclusion, multi-dimensional differential
display allows comparison of  sarcoidosis
spots with several ILD and granulomatous
diseases thereby providing robustness to the
identification of  spots with potential impor-
tance as biomakers of  sarcoidosis over dis-
eases with similar clinical presentation. Pro-
tein identification of  this array of  spots and
biological validation is the focus of  a sepa-
rate manuscript.
Future directions: Our current efforts are
directed towards a more comprehensive pro-
teome analysis using MudPit since we rec-
ognize that the current approach is limited
to the most abundant BAL species that were
resolved on 2DE-gels. Our long term goal is
to identify biomarkers able to assist the cli-
nician in the care of  sarcoidosis patients.
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